

## Devyser launches a new updated NGS assay to simplify thalassemia testing

Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed to further simplify genetic testing. The improved technology, will help broader screening for thalassemia with greater precision in detecting structural variants, saving time and ensuring better results for researchers worldwide.

This product will allow laboratories to achieve rapid, comprehensive results, reducing workflow complexity and enabling efficient genetic profiling through a single assay. Devyser Thalassemia v2 offers a streamlined protocol with minimal hands-on time, empowering labs to deliver reliable and reproducible results consistently.

“The Devyser Thalassemia product is one of our most successful products. With thalassemia affecting millions globally, the market for advanced genetic testing is projected to grow significantly. Devyser Thalassemia v2 positions the company as a leader in this expanding field. Our mission with the next generation of this product is to enable more comprehensive, simpler, and more reliable thalassemia testing for clinical researchers worldwide,” said Theis Kipling, CCO at Devyser. “This product embodies our commitment to providing state-of-the-art solutions for genetic research and advancing the field of thalassemia testing.”

Devyser Thalassemia v2 is currently available globally as a Research Use Only (RUO) product. For product details, visit: <https://devyser.com/devyser-thalassemia-v2>

### For more information, please contact:

Fredrik Dahl, interim CEO

E-mail: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50

Theis Kipling, CCO

E-mail: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50



**PRESS RELEASE**

04 February 2025 09:00:00 CET

### **About Devyser**

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit [www.devyser.com](http://www.devyser.com).